Bifogade filer
PDF
Kurs
+1,77%
Likviditet
0,75 MSEK
Kalender
| Est. tid* | ||
| 2026-06-04 | 07:00 | Bokslutskommuniké 2026 |
| 2026-03-02 | 07:00 | Kvartalsrapport 2026-Q3 |
| 2025-11-21 | - | Kvartalsrapport 2026-Q2 |
| 2025-11-10 | - | Extra Bolagsstämma 2025 |
| 2025-10-29 | - | Årsstämma |
| 2025-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2025-09-01 | - | Kvartalsrapport 2026-Q1 |
| 2025-06-03 | - | Bokslutskommuniké 2025 |
| 2025-03-03 | - | Kvartalsrapport 2025-Q3 |
| 2024-12-04 | - | Kvartalsrapport 2025-Q2 |
| 2024-09-26 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2024-09-25 | - | Årsstämma |
| 2024-08-29 | - | Kvartalsrapport 2025-Q1 |
| 2024-05-30 | - | Bokslutskommuniké 2024 |
| 2024-02-29 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-04 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-04 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2023-09-27 | - | Årsstämma |
| 2023-08-31 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-08 | - | Bokslutskommuniké 2023 |
| 2023-03-01 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-01 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-03 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2022-09-28 | - | Årsstämma |
| 2022-08-31 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-10 | - | Bokslutskommuniké 2022 |
| 2022-03-02 | - | Kvartalsrapport 2022-Q3 |
| 2021-12-02 | - | Kvartalsrapport 2022-Q2 |
| 2021-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2021-09-02 | - | Kvartalsrapport 2022-Q1 |
| 2021-05-31 | - | Bokslutskommuniké 2021 |
| 2021-03-03 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-02 | - | Kvartalsrapport 2021-Q2 |
| 2020-09-30 | - | Årsstämma |
| 2020-09-09 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2020-08-24 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-08 | - | Bokslutskommuniké 2020 |
| 2020-04-20 | - | Extra Bolagsstämma 2020 |
| 2020-03-02 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-02 | - | Kvartalsrapport 2020-Q2 |
| 2019-09-30 | - | Årsstämma |
| 2019-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2019-09-02 | - | Kvartalsrapport 2020-Q1 |
| 2019-06-10 | - | Bokslutskommuniké 2019 |
| 2019-03-04 | - | Kvartalsrapport 2019-Q3 |
| 2018-12-17 | - | Kvartalsrapport 2019-Q2 |
| 2018-09-25 | - | X-dag ordinarie utdelning INTEG B 0.00 SEK |
| 2018-09-24 | - | Årsstämma |
| 2018-09-24 | - | Kvartalsrapport 2019-Q1 |
| 2018-06-25 | - | Bokslutskommuniké 2018 |
| 2018-03-26 | - | Kvartalsrapport 2018-Q3 |
| 2017-12-18 | - | Kvartalsrapport 2018-Q2 |
| 2017-09-25 | - | Årsstämma |
| 2017-09-25 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-30 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Mölndal, 13 November 2025 - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B), today publishes, in connection with the ongoing rights issue, preliminary and unaudited financial key figures for the second quarter (August-October 2025) ahead of the interim report scheduled for publication on 21 November 2025.
Preliminary financial results, Q2 2025/26 (Aug-Oct 2025)
- Net sales: SEK 22.3 million (21.8), an increase of 2.6%.
- Operating result (EBIT): SEK -11.1 million (-11.3).
- Result after tax: SEK -7.4 million (-8.9).
- Earnings per share: SEK -0.35 (-0.46).
- Cash flow: SEK -19.4 million (-12.0).
- Cash and cash equivalents as of 31 October 2025: SEK 7.8 million (34.1).
- Equity ratio: 87.7% (89.8).
- S1 procedures: 43 (40).
Preliminary financial results, May-Oct 2025
- Net sales: SEK 46.1 million (40.2), an increase of 14.7%.
- Operating result (EBIT): SEK -23.5 million (-23.3).
- Result after tax: SEK -17.4 million (-18.4).
- Earnings per share: SEK -0.82 (-0.95).
- Cash flow: SEK -31.8 million (17.2).
The U.S. market continued to develop during the quarter, with sales of SEK 17.9 million (16.6), corresponding to a growth of 7.8 percent (currency-adjusted 18.4%). Sales in EMEA/APAC amounted to SEK 4.5 million (5.2). Cash flow was negatively affected by costs related to the terminated acquisition process with OsteoCentric Technologies.
The company continues to implement the strategic shift announced in February, with a focus on increased commercialization, cost efficiency, and expanded collaborations with leading orthopedic centers in the United States.
"Through the ongoing rights issue, we are strengthening Integrum's financial position and creating room for continued growth," says Martin Hillsten, CEO of Integrum.
The full interim report for the period May-October 2025/26 will be published on 21 November 2025.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-11-2025 17:56 CET.
For more information, please contact:
Martin Hillsten, CEO
Tel: +46 733 55 28 32
Email: martin.hillsten@integrum.se
Louise Wåhlin, CFO
Tel: +46 734 63 73 03
Email: louise.wahlin@integrum.se
Certified Adviser
The Company's Certified Adviser is DNB Carnegie Investment Bank AB (publ).